Glenmark Pharmaceuticals Limited — Financials & Forensics
Sector: Healthcare · NSE: GLENMARK · BSE: 532296 · ISIN: INE935A01035
17 Nov 2026
Add GLENMARK to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY21 | FY22 | FY23 | FY24 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | ₹10,944 Cr | ₹12,305 Cr | ₹12,990 Cr | ₹11,813 Cr | ₹16,983 Cr |
| EBITDA | ₹2,084 Cr | ₹2,320 Cr | ₹2,278 Cr | ₹1,195 Cr | ₹4,572 Cr |
| EBITDA margin | 19.1% | 18.9% | 17.5% | 10.1% | 26.9% |
| Profit after tax | ₹970 Cr | ₹994 Cr | ₹377 Cr | ₹-1,831 Cr | ₹1,362 Cr |
Deeper analysis
Recent filings by Glenmark Pharmaceuticals Limited
-
Press Release
17 Nov 2026 · General Update
-
Press Release
16 Nov 2026 · Corporate Action
-
Analysts/Institutional Investor Meet/Con. Call Updates
09 Nov 2026 · General Update
-
Analysts/Institutional Investor Meet/Con. Call Updates
06 Nov 2026 · Financial Results
-
Outcome of Board Meeting
05 Nov 2026 · Financial Results
Never miss a filing again
About Glenmark Pharmaceuticals Limited on Indian Stock Alerts
Indian Stock Alerts tracks Glenmark Pharmaceuticals Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.